China · Delayed Price · Currency is CNY Novogene Statistics
Total Valuation
Novogene has a market cap or net worth of CNY 6.30 billion. The enterprise value is 4.77 billion.
| Market Cap | 6.30B |
| Enterprise Value | 4.77B |
Important Dates
The last earnings date was Wednesday, April 15, 2026.
| Earnings Date | Apr 15, 2026 |
| Ex-Dividend Date | Jun 10, 2025 |
Share Statistics
Novogene has 405.06 million shares outstanding. The number of shares has decreased by -2.82% in one year.
| Current Share Class | 405.06M |
| Shares Outstanding | 405.06M |
| Shares Change (YoY) | -2.82% |
| Shares Change (QoQ) | +0.33% |
| Owned by Insiders (%) | 53.05% |
| Owned by Institutions (%) | 9.74% |
| Float | 136.65M |
Valuation Ratios
The trailing PE ratio is 38.89 and the forward PE ratio is 30.19.
| PE Ratio | 38.89 |
| Forward PE | 30.19 |
| PS Ratio | 2.78 |
| PB Ratio | 2.33 |
| P/TBV Ratio | 2.38 |
| P/FCF Ratio | 47.73 |
| P/OCF Ratio | 25.51 |
| PEG Ratio | n/a |
Enterprise Valuation
The stock's EV/EBITDA ratio is 16.24, with an EV/FCF ratio of 36.13.
| EV / Earnings | 29.34 |
| EV / Sales | 2.11 |
| EV / EBITDA | 16.24 |
| EV / EBIT | 30.87 |
| EV / FCF | 36.13 |
Financial Position
The company has a current ratio of 2.62, with a Debt / Equity ratio of 0.03.
| Current Ratio | 2.62 |
| Quick Ratio | 2.16 |
| Debt / Equity | 0.03 |
| Debt / EBITDA | 0.23 |
| Debt / FCF | 0.52 |
| Interest Coverage | 76.42 |
Financial Efficiency
Return on equity (ROE) is 6.36% and return on invested capital (ROIC) is 12.61%.
| Return on Equity (ROE) | 6.36% |
| Return on Assets (ROA) | 2.58% |
| Return on Invested Capital (ROIC) | 12.61% |
| Return on Capital Employed (ROCE) | 5.60% |
| Weighted Average Cost of Capital (WACC) | 8.18% |
| Revenue Per Employee | 1.02M |
| Profits Per Employee | 73,044 |
| Employee Count | 2,225 |
| Asset Turnover | 0.61 |
| Inventory Turnover | 5.06 |
Taxes
In the past 12 months, Novogene has paid 24.87 million in taxes.
| Income Tax | 24.87M |
| Effective Tax Rate | 12.93% |
Stock Price Statistics
The stock price has increased by +11.95% in the last 52 weeks. The beta is 0.73, so Novogene's price volatility has been lower than the market average.
| Beta (5Y) | 0.73 |
| 52-Week Price Change | +11.95% |
| 50-Day Moving Average | 14.34 |
| 200-Day Moving Average | 14.91 |
| Relative Strength Index (RSI) | 62.46 |
| Average Volume (20 Days) | 3,670,416 |
Short Selling Information
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | n/a |
Income Statement
In the last 12 months, Novogene had revenue of CNY 2.26 billion and earned 162.52 million in profits. Earnings per share was 0.40.
| Revenue | 2.26B |
| Gross Profit | 972.50M |
| Operating Income | 154.45M |
| Pretax Income | 192.33M |
| Net Income | 162.52M |
| EBITDA | 272.97M |
| EBIT | 154.45M |
| Earnings Per Share (EPS) | 0.40 |
Balance Sheet
The company has 1.63 billion in cash and 68.62 million in debt, with a net cash position of 1.56 billion or 3.85 per share.
| Cash & Cash Equivalents | 1.63B |
| Total Debt | 68.62M |
| Net Cash | 1.56B |
| Net Cash Per Share | 3.85 |
| Equity (Book Value) | 2.71B |
| Book Value Per Share | 6.61 |
| Working Capital | 1.74B |
Cash Flow
In the last 12 months, operating cash flow was 246.90 million and capital expenditures -114.94 million, giving a free cash flow of 131.96 million.
| Operating Cash Flow | 246.90M |
| Capital Expenditures | -114.94M |
| Depreciation & Amortization | 118.52M |
| Net Borrowing | -17.02M |
| Free Cash Flow | 131.96M |
| FCF Per Share | 0.33 |
Margins
Gross margin is 42.95%, with operating and profit margins of 6.82% and 7.18%.
| Gross Margin | 42.95% |
| Operating Margin | 6.82% |
| Pretax Margin | 8.49% |
| Profit Margin | 7.18% |
| EBITDA Margin | 12.06% |
| EBIT Margin | 6.82% |
| FCF Margin | 5.83% |
Dividends & Yields
This stock pays an annual dividend of 0.05, which amounts to a dividend yield of 0.28%.
| Dividend Per Share | 0.05 |
| Dividend Yield | 0.28% |
| Dividend Growth (YoY) | 5.26% |
| Years of Dividend Growth | 2 |
| Payout Ratio | 12.46% |
| Buyback Yield | 2.82% |
| Shareholder Yield | 3.11% |
| Earnings Yield | 2.58% |
| FCF Yield | 2.10% |
Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | |
| Lynch Upside | |
| Graham Number | |
| Graham Upside |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
Novogene has an Altman Z-Score of 4.88 and a Piotroski F-Score of 6.
| Altman Z-Score | 4.88 |
| Piotroski F-Score | 6 |